Immunotherapy最新文献_第2页

Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-17 DOI: 10.1080/1750743X.2025.2461987

Sophie Carlson, Tasha L Lin, Sarah M Larson

引用次数: 0

Immunotherapy rechallenge after significant toxicity - can it be done successfully?

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-24 DOI: 10.1080/1750743X.2025.2452838

Ashley Tan, Tara McSweeney, Nisha Sikotra, Brendan Adler, Tom van Hagen, Quentin Summers, Andrew Dean, Naomi van Hagen, Ashleigh DeMarie, Eli Gabbay, Timothy D Clay

{"title":"Immunotherapy rechallenge after significant toxicity - can it be done successfully?","authors":"Ashley Tan, Tara McSweeney, Nisha Sikotra, Brendan Adler, Tom van Hagen, Quentin Summers, Andrew Dean, Naomi van Hagen, Ashleigh DeMarie, Eli Gabbay, Timothy D Clay","doi":"10.1080/1750743X.2025.2452838","DOIUrl":"10.1080/1750743X.2025.2452838","url":null,"abstract":"Aim: We describe a single-center burden of admissions for irAE management and rechallenge feasibility.Methods: A retrospective single-center study of patients receiving immunotherapy between 2015-2018 assessing irAE and immunotherapy rechallenge outcomes.Results: 69 of 307 patients (22%) required 124 hospitalizations for irAEs. 8 required ICU admission (2.6%). 6 (1.9%) died from irAEs. Corticosteroids were used in 96% of admissions. Additional immunosuppression was required in 26 admissions (21%). 47 of 69 patients were rechallenged (68%). The median duration between toxicity and rechallenge was 49 days (range 17-994 days). 19 of 47 rechallenged patients (40%) were admitted for subsequent irAE. 19 patients of the rechallenged group (40%) were alive at last follow-up.Conclusion: Immunotherapy rechallenge following prior irAE hospitalization is feasible but carries significant toxicity risk.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"103-111"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Encouraging co-targeting of immunoregulatory molecules in cancer treatment.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-05 DOI: 10.1080/1750743X.2025.2462520

Takumi Sato, Yu Fujiwara

引用次数: 0

Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.1080/1750743X.2025.2467026

Tomoko Hasunuma, Clive Grattan, Takashi Eto, Michio Yagi, Rie Yazawa, Sunghyun Kim, Yunju Bae, Suyoung Kim, Jeong Eun Park, Jongho Kim, Sarbjit Saini

{"title":"Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe.","authors":"Tomoko Hasunuma, Clive Grattan, Takashi Eto, Michio Yagi, Rie Yazawa, Sunghyun Kim, Yunju Bae, Suyoung Kim, Jeong Eun Park, Jongho Kim, Sarbjit Saini","doi":"10.1080/1750743X.2025.2467026","DOIUrl":"10.1080/1750743X.2025.2467026","url":null,"abstract":"Aims: To demonstrate pharmacokinetic equivalence of CT‑P39 administered via auto-injector (CT‑P39 AI) and European Union-approved reference omalizumab via pre-filled syringe (EU-OMA PFS) in healthy Japanese adults.Participants & methods: This open-label, Phase 1 study randomized participants (1:1) to a single 150 mg/mL dose of CT‑P39 AI or EU-OMA PFS. The primary endpoint was pharmacokinetic equivalence per area under the concentration-time curve from time zero to infinity (AUC0-inf) and maximum serum concentration (Cmax). Equivalence was concluded if the 90% confidence intervals (CIs) for the ratios of geometric least-squares means (gLSMs) were contained within the predefined 80-125% equivalence margin. Secondary endpoints comprised additional pharmacokinetics, pharmacodynamics, safety, and immunogenicity.Results: Overall, 65 and 64 individuals were randomized to CT‑P39 AI and EU-OMA PFS, respectively. Pharmacokinetic equivalence between CT‑P39 AI and EU-OMA PFS was demonstrated for both AUC0-inf (ratio of gLSMs [90% CI] 101.66 [95.31-108.45]) and Cmax (93.91 [87.20-101.14]). Thirty-nine (60.0%; CT‑P39 AI) and 32 (50.8%; EU-OMA PFS) participants experienced treatment-emergent adverse events (TEAEs) with no serious TEAEs. Secondary endpoints were comparable between groups.Conclusions: CT‑P39 AI was pharmacokinetically equivalent to EU-OMA PFS following a single dose in healthy Japanese individuals; pharmacodynamics, safety, and immunogenicity were comparable.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"113-121"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Light-based technologies in immunotherapy: advances, mechanisms and applications.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-03-03 DOI: 10.1080/1750743X.2025.2470111

Davide Frumento, Ștefan Ţălu

{"title":"Light-based technologies in immunotherapy: advances, mechanisms and applications.","authors":"Davide Frumento, Ștefan Ţălu","doi":"10.1080/1750743X.2025.2470111","DOIUrl":"10.1080/1750743X.2025.2470111","url":null,"abstract":"Light-based immunotherapy uses specific wavelengths of light to activate or modulate immune responses. It primarily employs two mechanisms: direct activation of immune cells and indirect modulation of the tumor microenvironment (TME). Several light-based technologies are under investigation or clinical use in immunotherapy, including photodynamic immunotherapy (PDIT) and photothermal therapy (PTT). Optogenetic tools have the potential to precisely control T-cell receptor activation, cytokine release, or the activity of other immune effector cells. Light-based technologies present innovative opportunities within the realm of immunotherapy. The ability to precisely regulate immune cell activation via optogenetics, alongside the improved targeting of cancer cells through photoimmunotherapy, signifies a transformative shift in our strategies for immune modulation. Although many of these technologies remain in the experimental stage for various applications, initial findings are encouraging, especially concerning cancer treatment and immune modulation. Continued research and clinical trials are essential to fully harness the capabilities of light technology in the context of immune cell therapy.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"123-131"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy. 从天然卫士到治疗勇士：艾滋病免疫疗法中的 NK 细胞。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-05 DOI: 10.1080/1750743X.2025.2460965

Thessa Laeremans, Amber Janssens, Joeri L Aerts

{"title":"From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy.","authors":"Thessa Laeremans, Amber Janssens, Joeri L Aerts","doi":"10.1080/1750743X.2025.2460965","DOIUrl":"10.1080/1750743X.2025.2460965","url":null,"abstract":"Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells both play essential roles in controlling viral infections by eliminating virus-infected cells. Unlike CTLs, which require priming and activation by antigen-presenting cells, NK cells possess a remarkable capacity to mount a rapid antiviral immune response immediately after infection. Additionally, they can bolster the adaptive immune system by secreting cytokines and directly interacting with other immune cells. However, during chronic human immunodeficiency virus (HIV) infection, various immune cells, including NK cells, experience functional impairments. This has led to the exploration of NK cell-based immunotherapy as a promising strategy to reverse these dysfunctions and contribute to the pursuit of a functional cure for HIV. Building on the success of NK cell therapies in cancer treatment, these approaches offer significant potential for transforming the HIV cure field. This review provides a comprehensive overview of the latest advances in NK cell-based immunotherapy for HIV, outlining the progress made and the key challenges that must be overcome to achieve a functional cure for people living with HIV.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"133-145"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-11 DOI: 10.1080/1750743X.2025.2457931

David J Jackson, Girolamo Pelaia, Benjamin Emmanuel, Trung N Tran, David Cohen, Vivian H Shih, Anat Shavit, Douglas Arbetter, Rohit Katial, Adrian Paul J Rabe, Esther Garcia Gil, Marisa Pardal, Javier Nuevo, Michael Watt, Silvia Boarino, Sheena Kayaniyil, Claudia Chaves Loureiro, Alicia Padilla-Galo

引用次数: 0

ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-26 DOI: 10.1080/1750743X.2025.2464528

Emma Guttman-Yassky, Eric Simpson, Robert Bissonnette, Lawrence F Eichenfield, Kenji Kabashima, Paula C Luna, Janá Tresnak Hercogová, Lynda Spelman, Margitta Worm, Ehsanollah Esfandiari, Takahiro Arai, Hirotaka Mano, Prista Charuworn, Andrea Wang, Gregory Kricorian

{"title":"ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.","authors":"Emma Guttman-Yassky, Eric Simpson, Robert Bissonnette, Lawrence F Eichenfield, Kenji Kabashima, Paula C Luna, Janá Tresnak Hercogová, Lynda Spelman, Margitta Worm, Ehsanollah Esfandiari, Takahiro Arai, Hirotaka Mano, Prista Charuworn, Andrea Wang, Gregory Kricorian","doi":"10.1080/1750743X.2025.2464528","DOIUrl":"10.1080/1750743X.2025.2464528","url":null,"abstract":"Atopic dermatitis (AD) is a chronic inflammatory disease affecting ~ 10% of adults and ~ 20% of children globally. Many patients with moderate-to-severe AD receiving systemic therapies, including biologics and Janus kinase (JAK) inhibitors, fail to reach or maintain treatment goals due to lack of durable response or safety/tolerability issues. Rocatinlimab is a T-cell rebalancing therapy that inhibits and reduces pathogenic T cells by targeting the OX40 receptor. ROCKET, a large, global phase 3 program of eight clinical trials (NCT05398445; NCT05651711; NCT05724199; NCT05899816; NCT05704738; NCT05633355; NCT05882877; NCT06224192), will evaluate the efficacy, durability of response, and long-term safety of rocatinlimab as monotherapy and combination therapy in adult and adolescent patients with moderate-to-severe AD with or without prior exposure to biologics or systemic JAK inhibitors.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"83-94"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extended survival of a patient with gastrointestinal multiple malignancies managed with anti-PD-1 immunotherapy: a case report.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-11 DOI: 10.1080/1750743X.2025.2463309

Tianhao Guo, Yifan Hui, Wenjian Zhu, Fei Ke, Tingting Zhou, Wenli Qiu, Xuan Li, Liu Li, Haibo Cheng

{"title":"Extended survival of a patient with gastrointestinal multiple malignancies managed with anti-PD-1 immunotherapy: a case report.","authors":"Tianhao Guo, Yifan Hui, Wenjian Zhu, Fei Ke, Tingting Zhou, Wenli Qiu, Xuan Li, Liu Li, Haibo Cheng","doi":"10.1080/1750743X.2025.2463309","DOIUrl":"10.1080/1750743X.2025.2463309","url":null,"abstract":"Introduction: The annual rise in gastrointestinal cancer cases is evident, yet the occurrence of multiple primary malignancies remains comparatively uncommon. In recent years, immunotherapy has swiftly emerged as the leading treatment for several solid tumors, including gastrointestinal cancers. Single treatments might be ineffective, necessitating the need for comprehensive integrative medicine.Case description: This study reports a case of multiple cancers, including colorectal and gastric cancers. Diverse systemic treatments, like capecitabine, the combination of capecitabine and paclitaxel liposome, as well as capecitabine with toripalimab, were unsuccessful. Nevertheless, prolonged survival was attained through anti-PD-1 immunotherapy complemented by alternative medicine approaches. The patient has exceeded a 35-month survival post-initial diagnosis and 20-month survival since the subsequent diagnosis, markedly surpassing the prognosis often associated with advanced-stage multiple cancers.Conclusion: In summary, this case underscores the potential effectiveness of a holistic, integrative medical approach in managing advanced multiple malignancies amid drug resistance and disease progression.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"95-101"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies. Pegcetacoplan用于治疗因年龄相关性黄斑变性引起的地理萎缩：OAKS和DERBY临床研究的简单语言总结。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-01-17 DOI: 10.1080/1750743X.2025.2449760

Jeffrey S Heier, Eleonora M Lad, Frank G Holz, Philip J Rosenfeld, Robyn H Guymer, David Boyer, Federico Grossi, Caroline R Baumal, Jean-Francois Korobelnik, Jason S Slakter, Nadia K Waheed, Ravi Metlapally, Ian Pearce, Nathan Steinle, Anibal A Francone, Allen Hu, David R Lally, Pascal Deschatelets, Cedric Francois, Caleb Bliss, Giovanni Staurenghi, Jordi Monés, Rishi P Singh, Ramiro Ribeiro, Charles C Wykoff

引用次数: 0